Rocket Lab Q3 Shows Improved Cash Flow and Backlog Surge, but Neutron and Iridium Risks Persist

What happened

Rocket Lab reported Q3 2026 results with record revenue, a $1.2B sequential increase in backlog (up 52%), positive GAAP operating cash flow, and guidance for record revenue and gross margin expansion in Q4. This marks a notable improvement from the 1H 2026 trend of negative operating cash flow and margin compression highlighted in the prior master report. The backlog surge likely reflects strong demand across launch and space systems, reinforcing the top-line growth story. However, the press release does not address the two key risks that dominated the prior bear case: a dated Neutron first-flight window and visible progress on Iridium regulatory approvals. While the financials show encouraging momentum, the valuation still embeds high expectations, and the stock remains sensitive to execution on those strategic milestones.

Implication

Positive GAAP operating cash flow and guidance for gross margin expansion in Q4 address a key bear concern about cash burn and margin compression. The sequential backlog jump of $1.2 billion underscores strong demand, but recognition of that revenue is likely to be long-dated. Without a dated Neutron first-flight window or visible Iridium regulatory progress, the stock lacks the catalysts needed to re-rate toward the bull-case value of $55. At $45, the risk-reward is still unattractive relative to the base-case fair value of $41 and the attractive entry point near $36. We recommend waiting for the next program update or quarterly filing before adding exposure.

Thesis delta

The Q3 results improve the near-term financial picture by showing positive operating cash flow and gross margin expansion, which reduces the probability of the bear case. However, the master thesis remains unchanged because Neutron schedule credibility and Iridium closing remain unresolved and are the primary valuation drivers. Consequently, the rating shifts from potential sell to hold, with a re-assessment window of 3-6 months to monitor progress on those two catalysts.